United Therapeutics Corporation (UTHR)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

United Therapeutics Corporation (UTHR) is up 12.9% since the beginning of the year. At $550 per share, UTHR is trading 9.8% below its 52-week high of $609. Investors who bought $1,000 worth of UTHR shares 5 years ago would now be looking at an investment worth $3,126.

United Therapeutics Corporation (UTHR) has returned 12.85% so far this year and 71.99% over the past 12 months.

Based on dividend-adjusted daily data since Jun 17, 1999, UTHR's average daily return is +0.11%, while the average monthly return is +2.39%. At this rate, an investment would double in approximately 2.4 years.

Historically, 53% of months were positive and 47% were negative. The best month was Jun 2000 with a return of +71.0%, while the worst month was Dec 2000 at -69.6%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 6 months.

On a daily basis, UTHR closed higher 51% of trading days. The best single day was Aug 10, 2001 with a return of +58.9%, while the worst single day was Dec 4, 2000 at -62.3%.

United Therapeutics Corporation has an annualized alpha of 86.17%, beta of 0.09, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since June 18, 1999.

• This stock captured 101.89% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -412.78%) - a profile typical of hedging or uncorrelated assets.
• Beta of 0.09 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

UTHR ranks 88 for risk / return — in the top 88% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for United Therapeutics Corporation (UTHR) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the United Therapeutics Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the United Therapeutics Corporation was 93.18%, occurring on Dec 10, 2001. Recovery took 2282 trading sessions.

The current United Therapeutics Corporation drawdown is 7.86%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of United Therapeutics Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how United Therapeutics Corporation is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.